News | December 08, 2014

High-Quality Hospitals Deliver Lowest-Cost Care for Congenital Heart Surgery Patients

Study finds costs of care differed by five-fold across 27 hospitals


December 8, 2014 — Children’s hospitals in the United States delivering the highest-quality care for children undergoing heart surgery also appear to provide care most efficiently at a low cost, according to research led by the University of Michigan and presented at the American Heart Association Scientific Sessions in Chicago.

Congenital heart defects are the most common birth defects, and each year more than 30,000 congenital heart operations are performed across U.S. children’s hospitals. Congenital heart defects are also one of the most expensive pediatric conditions to treat.

Given the many current initiatives in healthcare aimed at both improving quality of care and reducing costs, or optimizing value, University of Michigan researchers along with collaborators decided to study whether it is possible to deliver high-quality heart care but also at a low cost. The study’s lead author was Sara K. Pasquali, M.D., associate professor of pediatric cardiology within the Michigan Congenital Heart Center at U-M’s C.S. Mott Children’s Hospital and U-M’s Center for Healthcare Outcomes and Policy.

The researchers studied 30,670 patients ages 0-18 years undergoing heart surgery across 27 different hospitals, using a unique dataset of merged clinical and cost information from the Society of Thoracic Surgeons and Children’s Hospital Association.

According to Pasquali, costs of care differed by five-fold across these hospitals. The lowest-cost hospitals had significantly lower mortality rates compared to the other hospitals. The low-cost hospitals also had shorter lengths of stay after surgery and fewer post-operative complications.

Interestingly, the low-cost hospitals tended to be larger volume centers, who were able to achieve these outcomes despite treating a more high-risk patient population.

“The care of children with congenital heart conditions is complex and requires significant investment of resources. It has been unclear whether there are centers able to provide high quality care, but also at a low cost,” said Pasquali, who is a member of the Institute for Healthcare Policy and Innovation at U-M.

“Understanding these relationships is critical in the appropriate design of policies aiming to optimize healthcare value in this population and others. For example, one would not want to provide incentives to low-cost hospitals if these low costs were due to poor clinical outcomes, such as high rates of mortality.”

What this new research shows, Pasquali said, is that lower-cost hospitals seem to be doing the right thing: They are delivering the highest-quality care to children undergoing heart surgery.

“In addition, these results suggest that initiatives that aiming to improve quality of care and outcomes, may also hold the potential to reduce costs in this population she says.

For more information: www.mottchildren.org/congenital


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now